AIDSTAR-One Co-trimoxazole Series: Resources to Increase & Sustain Use

Co-trimoxazole (also known as Septrin) is a well-tolerated, inexpensive, and cost-effective antimicrobial that reduces the risk of pneumonia, diarrhea, malaria, and other infections among people living with HIV. Although considered a standard of HIV care in higher-income countries, access to Co-trimoxazole is inconsistent in lower-income countries. Limited awareness of the benefits of Co-trimoxazole use among health care providers and service recipients is a key barrier to its access and use. Responding to this barrier, AIDSTAR-One developed and piloted provider and patient educational tools to increase appropriate prescription and use of co-trimoxazole for eligible people living with HIV. This collection includes those tools, a technical needs assessment report, and a summary report of the pilot project.

Cover of Septrin Dosage Formulations and Dosage for Infants, Children, and Adults Living with or Exposed to HIV

Septrin Dosage Formulations and Dosage for Infants, Children, and Adults Living with or Exposed to HIV

Co-trimoxazole (also known as Septrin) is a well-tolerated, inexpensive, and cost-effective antimicrobial that reduces the risk of pneumonia, diarrhea, malaria, and other infections among people living with HIV. Although considered a standard of HIV care in higher-income countries, access to Co-trimoxazole is inconsistent in lower-income countries. Limited awareness of the benefits of Co-trimoxazole use among health care providers and service recipients is a key barrier to its access and use.

Cover of Septrin Job Aid

Septrin Job Aid

Co-trimoxazole (also known as Septrin) is a well-tolerated, inexpensive, and cost-effective antimicrobial that reduces the risk of pneumonia, diarrhea, malaria, and other infections among people living with HIV. Although considered a standard of HIV care in higher-income countries, access to Co-trimoxazole is inconsistent in lower-income countries. Limited awareness of the benefits of Co-trimoxazole use among health care providers and service recipients is a key barrier to its access and use.

Cover of Septrin brochure

Adult Living with HIV: Septrin Brochure

Co-trimoxazole (also known as Septrin) is a well-tolerated, inexpensive, and cost-effective antimicrobial that reduces the risk of pneumonia, diarrhea, malaria, and other infections among people living with HIV. Although considered a standard of HIV care in higher-income countries, access to Co-trimoxazole is inconsistent in lower-income countries. Limited awareness of the benefits of Co-trimoxazole use among health care providers and service recipients is a key barrier to its access and use.

Cover of Co-Trimoxazole Management and Availability

Co-Trimoxazole Management and Availability: Logistics and Supply Chain Experience in 15 PEPFAR Countries

Co-trimoxazole is a simple, well-tolerated, inexpensive antibiotic. When taken regularly as prophylaxis, co-trimoxazole reduces mortality and specifically reduces the risk of pneumonia, diarrhea, malaria, and other opportunistic infections (OIs) in adults and children living with HIV. The World Health Organization (WHO) recommends co-trimoxazole is included as an integral component of the HIV chronic care package as it is key to pre-antiretroviral therapy (ART) care (WHO 2006). It is listed on WHO’s Model List of Essential Medicines in the “Other antibacterials” category (WHO 2010). Co-trimoxazole is also used in primary health care (PHC) to treat infections of the eyes, ears, skin, and genitourinary and respiratory tracts, among other infections (WHO 2008), thus rendering it a high-priority public health product.

Cover of Pilot Co-trimoxazole Tools Assessment, Gulu, Uganda

Pilot Co-trimoxazole Tools Assessment, Gulu, Uganda

Co-trimoxazole is a well-tolerated, inexpensive, and cost-effective antimicrobial that has been shown to reduce the risk of pneumonia, diarrhea, malaria, and other opportunistic infections among people living with HIV (PLHIV). However, limited awareness of the benefits of co-trimoxazole use among health care providers and service recipients continues to be a key barrier to its use (Anand et al. 2010). AIDSTAR-One developed provider and patient educational tools to increase appropriate prescription and use of co-trimoxazole for PLHIV eligible for its use and piloted these tools in Northern Uganda between May and August 2012. AIDSTAR-One conducted a mixed-methods assessment pre- and post-pilot to analyze the effectiveness and acceptability of the co-trimoxazole tools.